Multicenter study to characterize the molecular genetic features of exceptional response to radiotherapy
Not Applicable
Recruiting
- Conditions
- Cancers treated with radiotherapy
- Registration Number
- JPRN-UMIN000049867
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with a history of prior radiotherapy for lesions exhibiting exceptional response. 2) Patients unsuitable for the study judged by the principal investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identification of genetic alterations in tumor tissues such as somatic mutations, copy number alterations, aberrant expression, and structural variants
- Secondary Outcome Measures
Name Time Method Altered gene pathways, tumor immune response, germline mutations, overall survival, progression-free survival, local progression-free survival, duration of response
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular genetic features correlate with exceptional radiosensitivity in JPRN-UMIN000049867 observational cancer study?
How does JPRN-UMIN000049867 compare standard-of-care radiotherapy outcomes with exceptional responders in oncology?
Which biomarkers predict cancer patient response to radiotherapy in JPRN-UMIN000049867 multicenter observational trial?
What adverse events are associated with exceptional radiotherapy response in JPRN-UMIN000049867 and how are they managed?
How do DNA repair pathway mutations influence radiotherapy effectiveness in JPRN-UMIN000049867 and potential combination strategies?